Patents Assigned to Translate Bio, Inc.
-
Patent number: 11964051Abstract: Disclosed are cationic lipids which are compounds of Formula (I?). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.Type: GrantFiled: May 15, 2019Date of Patent: April 23, 2024Assignee: TRANSLATE BIO, INC.Inventors: Frank DeRosa, Shrirang Karve, Yi Zhang, Michael Heartlein
-
Patent number: 11951179Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: April 3, 2023Date of Patent: April 9, 2024Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Patent number: 11951180Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: April 3, 2023Date of Patent: April 9, 2024Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Patent number: 11951181Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: April 3, 2023Date of Patent: April 9, 2024Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Patent number: 11920182Abstract: The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.Type: GrantFiled: May 19, 2021Date of Patent: March 5, 2024Assignee: TRANSLATE BIO, INC.Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias
-
Patent number: 11890377Abstract: The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.Type: GrantFiled: January 29, 2021Date of Patent: February 6, 2024Assignees: Translate Bio, Inc., Massachusetts Institute of TechnologyInventors: Michael Heartlein, Daniel Anderson, Yizhou Dong, Frank DeRosa
-
Patent number: 11884692Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of (a) precipitating mRNA from an impure preparation; (b) subjecting the impure preparation comprising precipitated mRNA to a purification process involving membrane filtration such that the precipitated mRNA is captured by a membrane; and (c) eluting the captured precipitated mRNA from the membrane by re-solubilizing the mRNA, thereby resulting in a purified mRNA solution. In some embodiments, a purification process involving membrane filtration suitable for the present invention is tangential flow filtration.Type: GrantFiled: July 6, 2022Date of Patent: January 30, 2024Assignee: TRANSLATE BIO, INC.Inventors: Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
-
Patent number: 11820977Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.Type: GrantFiled: June 8, 2022Date of Patent: November 21, 2023Assignee: TRANSLATE BIO, INC.Inventors: Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
-
Publication number: 20230330262Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: ApplicationFiled: April 3, 2023Publication date: October 19, 2023Applicant: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Publication number: 20230293723Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: ApplicationFiled: April 3, 2023Publication date: September 21, 2023Applicant: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Publication number: 20230285593Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: ApplicationFiled: April 3, 2023Publication date: September 14, 2023Applicant: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Publication number: 20230285592Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: ApplicationFiled: April 3, 2023Publication date: September 14, 2023Applicant: Translate Bio, Inc.Inventors: Frank DeRosa, Braydon Charles Guild, Michael Heartlein
-
Patent number: 11730825Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: December 21, 2021Date of Patent: August 22, 2023Assignee: TRANSLATE BIO, INC.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein
-
Patent number: 11712463Abstract: The present invention provides, among other things, methods of treating Pompe disease, including administering to a subject in need of treatment a composition comprising an mRNA encoding acid alpha-glucosidase (GAA) at an effective dose and an administration interval such that at least one symptom or feature of Pompe disease is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.Type: GrantFiled: July 7, 2021Date of Patent: August 1, 2023Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Michael Heartlein
-
Patent number: 11692189Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) is substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.Type: GrantFiled: June 8, 2022Date of Patent: July 4, 2023Assignee: Translate Bio, Inc.Inventors: Frank DeRosa, Anusha Dias, Michael Heartlein, Shrirang Karve
-
Publication number: 20230150921Abstract: The present invention provides, in part, phenolic acid lipid compounds of Formula (I), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly canbe useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.Type: ApplicationFiled: March 31, 2021Publication date: May 18, 2023Applicant: Translate Bio, Inc.Inventors: Shrirang KARVE, Frank DEROSA, Apiwat WANGWEERAWONG, Saswata KARMAKAR
-
Publication number: 20230050301Abstract: The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.Type: ApplicationFiled: June 1, 2022Publication date: February 16, 2023Applicant: Translate Bio, Inc.Inventors: Frank DeRosa, Anusha Dias, Michael Heartlein
-
Patent number: 11559561Abstract: The present invention provides, among other things, methods and compositions for treating primary ciliary dyskinesia (PCD) based on mRNA therapy. The compositions used in treatment of PCD comprise an mRNA comprising a dynein axonemal heavy chain 5 (DNAH5) coding sequence and are administered at an effective dose and an administration interval such that at least one symptom or feature of PCD is reduced in intensity, severity, or frequency or has a delayed onset. mRNAs with optimized DNAH5 coding sequences are provided that can be administered without the need for modifying the nucleotides of the mRNA to achieve sustained in vivo function.Type: GrantFiled: January 7, 2020Date of Patent: January 24, 2023Assignee: TRANSLATE BIO, INC.Inventors: Anusha Dias, Darshan Parekh, Jeffrey S. Dubins, Christian Cobaugh, Shrirang Karve, Zarna Patel, Sara J. Dunaj, Frank DeRosa, Michael Heartlein
-
Patent number: 11560562Abstract: The present invention provides methods for large-scale production of a composition enriched for full-length mRNA molecules using an SP6 RNA polymerase and compositions produced using such methods and uses thereof.Type: GrantFiled: February 27, 2018Date of Patent: January 24, 2023Assignee: Translate Bio, Inc.Inventors: Anusha Dias, Daniel Crawford, Frank DeRosa, Jonathan Abysalh, Michael Heartlein
-
Patent number: 11547764Abstract: Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.Type: GrantFiled: December 20, 2021Date of Patent: January 10, 2023Assignee: TRANSLATE BIO, INC.Inventors: Braydon Charles Guild, Frank DeRosa, Michael Heartlein